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Our goal was to assess the value of surgical excision of benign papillomas of the breast diagnosed on percutaneous core biopsy by
determining the frequency of upgrade to malignancies and high risk lesions on a ﬁnal surgical pathology. We reviewed 67 patients
who had biopsies yielding benign papilloma and underwent subsequent surgical excision. Surgical pathology of the excised lesions
was compared with initial core biopsy pathology results. 54 patients had concordant benign core and excisional pathology. Cancer
(ductal carcinoma in situ and invasive ductal carcinoma) was diagnosed in ﬁve (7%) patients. Surgery revealed high-risk lesions
in 8 (12%) patients, including atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ. Cancer
and high risk lesions accounted for 13 (19%) upstaging events from benign papilloma diagnosis. Our data suggests that surgical
excision is warranted with core pathology of benign papilloma.
1.Introduction
While considered a benign diagnosis, intraductal papillomas
of the breast diagnosed with percutaneous core biopsy have
traditionally been managed by complete surgical excision to
carefully examine the entire papilloma and adjacent breast.
Reasons to excise percutaneously diagnosed papillomas
include diﬃculties in pathologic interpretation (particularly
in the distinction of benign papillomas from papillary
carcinomas), association with adjacent high risk lesions or
cancers, and the premalignant potential of these lesions [1].
Over the past ten years though, some studies have
suggestedthatbenignpapillomasdiagnosedwithcorebiopsy
may be clinically followed rather than surgically excised.
The management of intraductal papillomas has thus become
controversial with some advocating surgical excision of all
lesions despite benign pathologic features, whereas others
excise only those specimens with atypical papillary features
[2].
We sought to examine the degree of pathologic con-
cordance between percutaneous core biopsy yielding benign
papilloma and ﬁnal excisional histology, thus contributing
to guidelines regarding management of benign papillary
lesions diagnosed on core biopsy. Because our study was
conducted at a community hospital, we seek to translate our
results, conclusions, and their implications to the general
population.
2.MaterialsandMethods
The study was approved by the institutional review board of
Atlantic Health at Morristown Medical Center, Morristown,
NJ. In our retrospective observational study we evaluated
81 consecutive patients that were diagnosed with benign
papilloma by core biopsy at Carol W. and Julius A. Rippel
Breast Center from January 2006 to January 2010.
The pathologies of 81 patients were determined to meet
the inclusion criteria of a benign, concordant papilloma
by percutaneous core biopsy. Any papillary lesion with
atypicalfeaturesdiagnosedoncorebiopsywasexcludedfrom
the study. Our investigation was to assess upgrade rate of
purely benign papillary lesions diagnosed on core biopsy.
All lesions were discovered by screening mammogram and2 Radiology Research and Practice
Table 1: Final pathology of 67 lesions following surgical excision.
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Table 2: Summary of literature: Benign papillary lesions diagnosed with core needle biopsy and followed up with surgical excision.
Year Refererence Sample size Excisional pathology
Benign Upgrade Malignant Atypia Final recommendation
2011 Our work 67 54 (81%) 13 (19%) 5 (7%) 8 (12%) Excision
2009 [2] 29 28 (97%) 1 (3%) 1 (3%) 0 (0%) No excision
2008 [15] 48 38 (79%) 10 (21%) 7 (15%) 3 (6%) Excision
2008 [6] 86 65 (75%) 21 (25%) 9 (10%) 12 (14%) Excision
2007 [8] 80 54 (67.5%) 26 (32.5%) 15 (18.8%) 11 (14%) Excision
2007 [4] 38 37 (97%) 1 (2.6%) 1 (2.6%) 0 (0%) No excision
2007 [16] 20 13 (65%) 13 (65%) 7 (35%) 4 (20%) Excision
2007 [12] 36 30 (84%) 5 (14%) 5 (14%) 0 (0%) Excision
2006 [10] 25 20 (80%) 5 (20%) 5 (20%) 0 (0%) Excision
2006 [17] 36 14 (39%) 10 (28%) 2 (5.5%) 8 (22%) Excision
2006 [13] 37 32 (86%) 5 (14%) 5 (14%) 0 (0%) No excision
2004 [14] 6 6 (100%) 0 (0%) 0 (0%) 0 (0%) No excision
2004 [11] 13 9 (69%) 4 (31%) 2 (15.5) 2 (15.5%) Excision
2004 [5] 8 8 (100%) 0 (0%) 0 (0%) 0 (0%) No excision
2004 [3] 11 11 (100%) 0 (0%) 0 (0%) 0 (0%) No excision
2003 [18] 31 29 (94%) 2 (6%) 2 (6%) 0 (0%) Excision
2002 [19] 14 11 (78%) 3 (21%) 1 (7%) 2 (14%) No excision
subsequent diagnostic workup with mammography and
ultrasound. The 67 lesions were identiﬁed in 67 individual
women. The biopsy methods included stereotactic core
biopsy,ultrasound-guidedcorebiopsy,andMRI-guidedcore
biopsy. The stereotactic core biopsies were performed on
a LoRad table with a SenoRx 11 Gauge vacuum-assisted
core biopsy needle. The ultrasound-guided biopsies were
performed utilizing a GE ultrasound for visualization of the
lesion and a BARD monopty 14G needle for core biopsy.
MRI-guided biopsies were performed using a 1.5 T GE Signa
Excite system with a 7CH Invivo biopsy breast array coil
for visualization and a 10 Gauge SenoRx EnCore vacuum-
assisted core needle for biopsy.
All core biopsy results were compared with the ﬁnal
pathology upon surgical excision. Of the 81 patients, 67
women underwent subsequent surgical excision of papil-
loma, while 7 patients elected not to undergo the excision
and seven were lost to follow up. Histopathologic examina-
tion was performed on the 67 lesions from the patients who
underwent percutaneous core needle biopsy and subsequent
excision of the benign papillomas.
3. Results and Discussion
Fifty-four of the sixty-seven lesions that underwent sur-
gical excision were benign, accounting for 81% of the
ﬁnal pathology. Cancer was found on excision in ﬁve of
the sixty-seven lesions which underwent surgical excision,
accounting for 7% of the pathology. This resulted in 7%
upstaging rate from benign papilloma to carcinoma upon
ﬁnal surgical excision. Of the diagnosed cancer, 2 out of 5
(40%) were ductal carcinoma in situ (DCIS) and 3 out of
5 (60%) were invasive ductal carcinoma. In addition, high-
risk lesions including atypical ductal hyperplasia (ADH),
atypical lobular hyperplasia (ALH), and lobular carcinoma
in situ (LCIS) were identiﬁed in 8 out of 67 lesions upon
subsequent surgical excision, accounting for 12% of the ﬁnal
pathology. Of the eight high-risk lesions, 75% were ADH,
12.5% were ALH, and 12.5% were LCIS. Overall, there was
discordance of 19% between percutaneous core biopsy and
surgical excisional pathology (Table 1).
There is a general consensus that papillomas with atyp-
ical features diagnosed on percutaneous core needle biopsyRadiology Research and Practice 3
warrant surgical excision [3–6]. However, controversy per-
sists regarding management of papillomas without atypical
features. Across multiple series in the literature, a signiﬁcant
number of core biopsies that have yielded benign or bland
papillomas resulted in a considerable upgrade rate to atypia
and/or cancer upon surgical excisional pathology [6–11].
Many investigators have suggested that all papillary lesions
diagnosed with percutaneous core biopsy, regardless of the
presence or degree of atypia, should be surgically excised
[6–12]. Alternatively, others have argued [2–5, 13, 14] that,
while atypical papillary lesions found at core biopsy should
be surgically excised, those lesions which have no atypical
features at core biopsy may be managed conservatively
with clinical and mammographic or sonographic followup.
Therefore, there is uncertainty in management guidelines
for the patients diagnosed with benign papillary lesion on
percutaneous core biopsy.
Review of the literature reveals that many of the pub-
lished studies in the past decade which investigated the
upgrade rate of benign papillomas found on percutaneous
core biopsies were limited by small sample size and at
least fourteen studies have included less than 50 patients
(Table 2). Four out of these studies, those of Ahmadiyeh,
Sydnor, Renshaw and Agoﬀ, each independently concluded
that benign papillomas at core biopsy are infrequently
associated with malignancy at excision (0–3%) and may
be followed clinically and mammographically. Three out of
these four studies [2, 3, 5] reported that none of the papillary
lesionswithoutatypiawereassociatedwithcarcinoma.Inthe
paper by Sydnor et al. [4], only 1 out of 13 (3%) excised
benign papillomas was upgraded to malignancy at excision.
While these four studies suggest that surgical excision is
not necessary for percutaneously diagnosed benign papillary
lesions, they were limited to the sample size of 8 to 38
patients.
Thestudiesfrominstitutionswiththelargersamplesizes,
including our own, are in consensus that papillary lesions
should be excised for complete pathologic diagnosis as their
results show an increased risk of coexistent carcinoma upon
surgical excision. Results from Skandarajah et al. in 2007 and
Rizzoetal.in2008hadsamplesizesof86and80,respectively
and supported excision of benign bland papillomas. Perhaps
the most convincing data is from Skandarajah et al., who
reported that 26 out of 80 (33%) papillary lesions without
atypia were associated with upgrade to atypia or malignancy
at surgical excision. This data suggested that one out of three
patients undergoing core needle biopsy alone would have
missed the diagnosis of atypia or cancer.
With a sample size of 67 patients, we have one of the
largest sample sizes in the literature that speciﬁcally target
upgraderatesfrombenignpapillomasfoundatpercutaneous
core biopsy. Our results demonstrate an upgrade rate of 19%
including 7% upgrade to malignancy. These ﬁndings suggest
that one out of ﬁve patients undergoing percutaneous core
biopsy alone will be misdiagnosed.
The limitations of our study include the small sample
size, which is however one of the largest sample sizes among
published papers on the same topic. In addition, the patients
with upgraded lesions on surgical excision were not followed
toassessfortheclinicaloutcome.Whileweassumethatthere
is clinical beneﬁt in diagnosing cancer, which would have
been missed with the percutaneous core biopsy alone, it is
uncertain whether surgical excision of those lesions which
were upgraded to atypia actually changed morbidity and
mortality.
4. Conclusion
Given that we have one of the largest samples sizes in the
published literature, our results lend signiﬁcant support to
the existing data which suggests excision of benign bland
papillary lesions diagnosed on percutaneous core biopsy.
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